Retatrutide, explained: the triple agonist in the literature

Retatrutide has become the most-searched name in its class, and most of what ranks for it is either a clinical-trial press release or a sales page. This is neither. It's a description of what the molecule is, where it sits in the literature and in regulation, and what matters when it is supplied as a research compound.

What it is

Retatrutide — development code LY3437943 — is a synthetic peptide developed by Eli Lilly. It's a 39-residue sequence built on the backbone of glucose-dependent insulinotropic polypeptide (GIP), modified so that it also binds and activates the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor, and carrying a fatty-acid side chain that extends its circulating half-life by binding to albumin.

The chemistry is described in the medicinal-chemistry paper by Coskun and colleagues (2022), which reports the receptor pharmacology in cell assays and the design logic behind the three-way balance.

Approximate molecular mass is 4,731 Da. That figure — or the manufacturer's stated theoretical mass — is what an HPLC-MS certificate should be checked against.

Three receptors, and why that's the headline

The incretin class of peptides is usually described by the receptors it targets:

GLP-1 and GIP are the two incretin hormones — released from the gut after a meal, acting on the pancreas and on appetite-regulating circuits in the brain. Glucagon is the counter-regulatory hormone, released by the pancreas to raise blood glucose and increase energy expenditure. Combining agonism at all three in one molecule is the design idea; what that combination does in a human is the subject of the trial programme, not of this page.

In cell-based research the compound is used to study signalling at each receptor individually and the interplay between them — which is what "researched across appetite, blood-sugar regulation and energy metabolism" on our product page refers to.

Where it is in the literature

• Preclinical and chemistry. Coskun et al., Cell Metabolism, 2022 — design, in-vitro receptor activity, animal pharmacology.
• Phase 1. First-in-human single- and multiple-ascending-dose studies were published alongside the phase 2 programme.
• Phase 2 — adults with obesity. Jastreboff et al., New England Journal of Medicine, 2023. A 48-week randomised, placebo-controlled trial.
• Phase 2 — type 2 diabetes. Rosenstock et al., The Lancet, 2023.
• Phase 3. The TRIUMPH programme (obesity and related conditions) and TRANSCEND programme (type 2 diabetes) are under way, with results emerging through 2025 and 2026.

We link the papers below. We don't reproduce the numbers, because a page that sells the compound is not the place to read them from.

Regulatory status in the UK

Retatrutide is an investigational compound. At the time of writing it has no marketing authorisation from the MHRA, the EMA, the FDA or any other regulator, and it cannot be prescribed. It is lawful to buy, sell and hold in the UK for laboratory research; it cannot be sold or advertised for human or veterinary use.

That is the whole of its status. A vendor who describes it in any other terms is describing something that doesn't exist yet.

What matters for a research supply

For a laboratory the questions are the same as for any peptide, and none of them are about what the compound does:

1. Identity. The certificate should show an observed mass that agrees with the theoretical mass. Here's how to read the document.
2. Purity. By HPLC, with the method stated. The current Biovanta batch figure is on the product page, lifted from the certificate; what that percentage does and doesn't mean is covered here.
3. Batch traceability. Certificate, carton and the batch lookup should agree.
4. Cold chain. Retatrutide is supplied by Biovanta as a solution in a pre-filled pen, which means it is stored at 2–8°C from fill to fridge. Storage and the cold chain, explained.

How Biovanta supplies it

Retatrutide 40 mg, manufactured in Switzerland, in a pre-filled pen with sterile needles and prep swabs, held refrigerated in the UK and dispatched next working day. Manufacturer HPLC-MS certificate available before you order, and an independent Janoshik report per batch as each completes — the testing page shows which batches have one and lets you verify it by key. Supplied strictly for in-vitro laboratory research.